Abstract | BACKGROUND: METHODS: Women were allocated randomly to one of six groups, to receive intrathecal morphine 0.05, 0.1 or 0.2 mg plus oral dextromethorphan 60 mg or placebo. RESULTS: The addition of dextromethorphan did not reduce postoperative pain scores (P=0.83). Compared with women receiving intrathecal morphine 0.05 mg, women receiving higher doses had a significantly higher incidence of nausea and vomiting [odds ratio for intrathecal morphine 0.1 mg, 4.0 (95% confidence interval 1.2-14.1); for intrathecal morphine 0.2 mg, 7.9 (2.3-27.1)]. Compared with women receiving intrathecal morphine 0.05 mg, women receiving higher doses also had a significantly higher incidence of pruritus [odds ratio for intrathecal morphine 0.1 mg, 3.2 (95% confidence interval 1.3-8.2); for intrathecal morphine 0.2 mg, 3.7 (1.4-9.5)]. Women receiving dextromethorphan had a lower incidence of nausea and vomiting [odds ratio 2.6 (1.1-6.3)]. CONCLUSIONS:
|
Authors | D M A Choi, A P Kliffer, M J Douglas |
Journal | British journal of anaesthesia
(Br J Anaesth)
Vol. 90
Issue 5
Pg. 653-8
(May 2003)
ISSN: 0007-0912 [Print] England |
PMID | 12697594
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Analgesics, Opioid
- Excitatory Amino Acid Antagonists
- Receptors, N-Methyl-D-Aspartate
- Dextromethorphan
- Morphine
|
Topics |
- Adult
- Analgesia, Obstetrical
(methods)
- Analgesics, Opioid
(administration & dosage, adverse effects)
- Anesthesia, Obstetrical
(methods)
- Anesthesia, Spinal
- Cesarean Section
- Dextromethorphan
(administration & dosage)
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Excitatory Amino Acid Antagonists
(therapeutic use)
- Female
- Humans
- Morphine
(administration & dosage, adverse effects)
- Pain Measurement
(methods)
- Pain, Postoperative
(prevention & control)
- Postoperative Nausea and Vomiting
(chemically induced, prevention & control)
- Pregnancy
- Prospective Studies
- Pruritus
(chemically induced)
- Receptors, N-Methyl-D-Aspartate
(antagonists & inhibitors)
|